Results 81 to 90 of about 134,499 (99)
International audienceGA101 is a novel glycoengineered Type II CD20 monoclonal antibody. When compared with rituximab, it mediates less complement-dependent cytotoxicity (CDC).
Christian Klein +2 more
exaly +2 more sources
International audienceGA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II humanized antibody that targets the CD20 antigen expressed at the surface of B-cells.
Abdel Aouacheria +2 more
exaly +2 more sources
International audiencePurposeObinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models.
Gilles Salles +2 more
exaly +2 more sources
Epitope Characterization and Crystal Structure of GA101 Provide Insights Into the Molecular Basis for Type I/II Distinction of CD20 Antibodies [PDF]
CD20 is a cell-surface marker of normal and malignant B cells. Rituximab, a monoclonal antibody targeting CD20, has improved the treatment of malignant lymphomas.
Christian Klein +2 more
exaly +2 more sources
Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma.
Andre H Goy +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Journal of Immunology | Oxford Academic
Journal of Immunology, 2011Martino Introna +2 more
exaly

